Skip to main content

IgA Nephropathy clinical trials at UCLA

4 in progress, 1 open to eligible people

Showing trials for
  • Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18-75

    The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).

    Los Angeles, California and other locations

  • Atrasentan in Patients With Proteinuric Glomerular Diseases

    Sorry, in progress, not accepting new patients

    The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

    Glendale, California and other locations

  • LNP023 in Primary IgA Nephropathy Patients

    Sorry, in progress, not accepting new patients

    The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

    Los Angeles, California and other locations

  • Atrasentan in Patients With IgA Nephropathy

    Sorry, in progress, not accepting new patients

    The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

    Los Angeles, California and other locations

Our lead scientists for IgA Nephropathy research studies include .

Last updated: